CN115475192A - 一种应用具有降血脂活性的油橄榄果提取物 - Google Patents
一种应用具有降血脂活性的油橄榄果提取物 Download PDFInfo
- Publication number
- CN115475192A CN115475192A CN202211203977.4A CN202211203977A CN115475192A CN 115475192 A CN115475192 A CN 115475192A CN 202211203977 A CN202211203977 A CN 202211203977A CN 115475192 A CN115475192 A CN 115475192A
- Authority
- CN
- China
- Prior art keywords
- fruit extract
- olive fruit
- blood fat
- olive
- macroporous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000007817 Olea europaea Species 0.000 title claims abstract description 38
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 210000004369 blood Anatomy 0.000 title abstract description 21
- 239000008280 blood Substances 0.000 title abstract description 21
- 230000001603 reducing effect Effects 0.000 title abstract description 15
- 150000002632 lipids Chemical class 0.000 title description 6
- 235000002725 Olea europaea Nutrition 0.000 title description 4
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 33
- 239000011347 resin Substances 0.000 claims abstract description 16
- 229920005989 resin Polymers 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 238000003795 desorption Methods 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 2
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 238000010172 mouse model Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000000055 hyoplipidemic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- -1 divinyl phenyl Chemical group 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
本发明涉及一种应用大孔树脂制备油橄榄果中具有降血脂活性部位的方法。通过本方法可以获得具有降血脂活性的油橄榄果提取物,经过小鼠模型体内活性试验验证具有良好的降血脂作用。在不同剂量水平下,均能实现良好的降血脂作用,且具有较好的量效关系。本发明分离成本低,制备过程安全,采用大孔树脂制备技术,能够快速从油橄榄果中分离制备得到具有降血脂活性的油橄榄果提取物,整个分离方法适合于工业化生产。
Description
技术领域
本发明属于天然产物制备应用技术领域,具体涉及一种应用具有降血脂活性的油橄榄果提取物。
背景技术
高脂血症(Hyperlipidemia,HLP)又称血脂异常和高脂蛋白血症,是临床上常见而多发的一种以全身性的脂质代谢紊乱为特征的慢性代谢性疾病。高脂血症与其它心血管疾病风险因素相互作用,容易导致动脉粥样硬化、冠心病、中风、脑梗死等诸多心脑血管疾病;还与糖尿病、胰腺炎、神经退行性疾病(如阿尔兹海默病)、肥胖症和脂肪肝等疾病密切相关,严重危害人类健康。随着人们生活方式和饮食结构的巨大变化,高脂血症的发病率也显著增高。据估计,2022年全球患血脂异常的人数将达到7800万,其中1/6的病例将发生在中国。在全球死亡率中高脂血症及其并发症占比达50%,临床常用药辛伐他汀、普伐他汀、洛伐他汀等已被广泛用于临床来治疗高脂血症,并且取得了良好的效果。而对于那些血脂普遍偏高,波动频繁,但并没有达到病理指标的亚健康人群,如何在不摄入药物的前提下有效预防高血脂的发生,是科学研究的主要方向之一,也是全民健康的迫切需求。
油橄榄果又称齐墩果,是木犀科木犀榄属油料作物木犀榄(Olea europaea L.)的果实,油橄榄鲜果中含橄榄油约20%、水50%、其它成分30%,橄榄油因其丰富的营养和功能活性成分,有“液体黄金”和“植物油皇后”的美誉。据报道,多酚类物质如羟基酪醇、橄榄苦苷和黄酮类等具有抗氧化、抗炎、降血脂等多种生物活性。前期研究发现,简单提取的油橄榄果提取物在降血脂试验中,无法达到较好的效果。
发明内容
本发明的目的是提供一种应用具有降血脂活性的油橄榄果提取物,能够在相对低剂量的情况下达到降血脂的效果。
本发明所提供的油橄榄果提取物,其制备方法如下:
1)将油橄榄果粉碎至糊状,然后加入5-15倍量的水或者乙醇水溶液,加热回流提取,提取后过滤得到上清液,减压浓缩后作为上样液;
2)将上样液经过大孔吸附树脂柱进行吸附,吸附后的树脂柱先用纯净水进行洗涤,然后加入不同浓度的乙醇水溶液对大孔树脂柱进行梯度解吸附;收集50%-90%的乙醇洗脱液,减压浓缩干燥,得到油橄榄果提取物;
优选地,所述大孔吸附树脂为苯乙烯和二乙烯基苯基质交联得到的大孔吸附树脂;其中使用AB-8、XDA-8、D101、HPD700、LX-21中的一种或者多种最佳。
用本发明所制备的油橄榄果降血脂活性提取物可以用于制备药物或保健品,用于治疗和预防高脂血症及高脂血症引起的非酒精性脂肪肝、动脉粥样硬化等心血管和内分泌系统疾病。
本发明的制备的油橄榄果提取物经体内活性评价其降血脂作用显著。
具体实施方式
为了进一步提高油橄榄果提取物的活性,本发明提供了一种高效分离富集的方法,在本发明技术下制备的油橄榄果提取物,在相对剂量水平下,均具有显著的降血脂作用。
本发明的降血脂活性检测方法如下:采用金黄地鼠高血脂小鼠模型,在不同剂量下灌胃给与上述制备的油橄榄果提取物,经过5周给药后检测小鼠血脂水平,发现制备的油橄榄果提取物在不同剂量水平下,均能实现较好的降血脂作用,且具有较好的量效关系。
下面结合具体实施例对本发明提供的应用大孔树脂制备油橄榄果降血脂弧形部位的方法进行详细的说明。
实施例1提取油橄榄果提取物
称取新鲜油橄榄果1000g,放入粉碎机中打碎,呈糊状;第一次加入15L水,加热提取1.5h,过滤得到上清液;然后加入10倍量水,加热提取1.5h。将两次提取液合并后减压回收溶剂,浓缩至体积2L,相当于原料0.5g/mL,作为上样液准备上大孔树脂柱吸附。
使用XDA-8大孔树脂,经过处理后装柱。将上样液加入大孔树脂柱中进行吸附,吸附流速2BV/h。吸附完毕后,先用纯净水洗脱除杂,流速4BV/h。然后用80%的乙醇解吸附,流速4BV/h。收集解吸附液,减压回收溶剂后微波干燥,得到油橄榄果提取物24.2g。
实施例2:油橄榄果提取物的降血脂的效果
采用金黄地鼠高血脂小鼠模型,选取小鼠40只,体重20-22g,按血脂水平随机分成4组,每组10只,雌雄各半,分别为模型组、油橄榄果提取物剂量组(100、300mg/kg),阳性药辛伐他汀组。各组每天灌胃给药一次,连续5周。于给药后5周后眼眶静脉丛取血0.3mL,高速离心后取血清用全自动生化仪检测血脂指标总胆固醇(TC)、总甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)。实验结果表明油橄榄果提取物具有降血脂作用(表1)。
给药组与模型组比较*p<0.05**p<0.01
结果表明,试验期间各组小鼠体重间未发现显著性差异,油橄榄果提取物高剂量组(300mg/kg)、低剂量组(100mg/kg)的小鼠血清的低密度脂蛋白胆固醇(LDL-C)含量极显著低于模型组(P<0.01);提取物高剂量组小鼠血清中总胆固醇(TC)含量显著低于模型组(P<0.05);提取物高剂量组小鼠血清中总甘油三酯(TG)含量显著低于模型组(P<0.05),提取物低剂量组小鼠血清中总甘油三酯(TG)含量极显著低于模型组(P<0.01)。表明本方法制备的油橄榄果提取物在不同剂量水平下,均能实现降血脂作用,且具有较好的量效关系。
Claims (6)
1.一种油橄榄果提取物,其特征在于,所述的油橄榄果提取物的制备方法如下:
1)将油橄榄果粉碎至糊状,然后加入水或者乙醇水溶液,加热回流提取,提取后过滤得到上清液,减压浓缩后作为上样液;
2)将上样液经过大孔吸附树脂柱进行吸附,吸附后的树脂柱先用纯净水进行洗涤,然后加入不同浓度的乙醇水溶液对大孔树脂柱进行梯度解吸附;收集50%-90%的乙醇洗脱液,减压浓缩干燥,得到油橄榄果提取物。
2.如权利要求1所述的油橄榄果提取物,其特征在于,所述的2)中的大孔吸附树脂为苯乙烯和二乙烯基苯基质交联得到的大孔吸附树脂。
3.如权利要求1所述的油橄榄果提取物,其特征在于,所述的大孔吸附树脂为AB-8、XDA-8、D101、HPD700或LX-21。
4.权利要求1所述的油橄榄果提取物在制备用于预防和治疗高血脂的制品中的应用。
5.一种用于预防或治疗高血脂的制品,其特征在于,所述的制品中包含有权利要求1所述的油橄榄果提取物。
6.如权利要求5所述的制品,其特征在于,所述的制品为功能性食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211203977.4A CN115475192A (zh) | 2022-09-29 | 2022-09-29 | 一种应用具有降血脂活性的油橄榄果提取物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211203977.4A CN115475192A (zh) | 2022-09-29 | 2022-09-29 | 一种应用具有降血脂活性的油橄榄果提取物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115475192A true CN115475192A (zh) | 2022-12-16 |
Family
ID=84393888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211203977.4A Pending CN115475192A (zh) | 2022-09-29 | 2022-09-29 | 一种应用具有降血脂活性的油橄榄果提取物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115475192A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169771A (zh) * | 2011-12-23 | 2013-06-26 | 中国科学院兰州化学物理研究所 | 从油橄榄果渣中提取含有山楂酸和齐墩果酸混合物的方法 |
CN113230312A (zh) * | 2021-05-28 | 2021-08-10 | 中国科学院兰州化学物理研究所 | 一种油橄榄果中降血脂活性组分的提取方法及降血脂活性组分、降血脂活性组分的评估方法 |
-
2022
- 2022-09-29 CN CN202211203977.4A patent/CN115475192A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169771A (zh) * | 2011-12-23 | 2013-06-26 | 中国科学院兰州化学物理研究所 | 从油橄榄果渣中提取含有山楂酸和齐墩果酸混合物的方法 |
CN113230312A (zh) * | 2021-05-28 | 2021-08-10 | 中国科学院兰州化学物理研究所 | 一种油橄榄果中降血脂活性组分的提取方法及降血脂活性组分、降血脂活性组分的评估方法 |
Non-Patent Citations (1)
Title |
---|
孙小明;裴栋;刘晔玮;邸多隆;: "辅料对油橄榄叶提取物中橄榄苦苷与羟基酪醇稳定性的影响", 中国现代应用药学 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101107952B (zh) | 一种滇橄榄保健茶及其制备方法 | |
CA2987979A1 (en) | Solvent-free thca extraction process | |
CN101185665A (zh) | 鬼针草总黄酮的制备方法 | |
CN102247420B (zh) | 一种墨旱莲提取物的制备方法及用途 | |
CN102526315B (zh) | 一种荔枝核有效部位群提取物的制备方法 | |
CN102652801A (zh) | 一种降血糖及防治糖尿病并发症的中草药袋泡茶 | |
CN104258193A (zh) | 一种治疗神经衰弱和预防老年痴呆症的药物组合物 | |
KR101052574B1 (ko) | 인삼으로부터 진세노사이드 Rg1 또는 Rb1이 강화된 추출물 분획을 제조하는 방법 | |
CN101107950B (zh) | 一种山楂保健茶及其制备方法 | |
CN108785370B (zh) | 一种用于治疗高血脂症及动脉粥样硬化的药物组合物 | |
JP7161064B2 (ja) | エルダーベリー抽出物を有効成分として含む男性更年期症候群の予防、治療または改善用の組成物 | |
CN102688284A (zh) | 薰衣草总黄酮的制备方法 | |
CN104606276A (zh) | 一种从柿叶中提取小分子柿叶黄酮的方法 | |
CN115475192A (zh) | 一种应用具有降血脂活性的油橄榄果提取物 | |
CN101327232A (zh) | 一种采用聚酰胺分离纯化沙棘黄酮的制备方法及其应用 | |
CN105832820A (zh) | 一种香椿叶辅助降血糖饮片及其制备方法 | |
CN106924299B (zh) | 一种黑木耳提取物及其在降血脂药物及保健食品中的应用 | |
CN102613347A (zh) | 银杏黑茶及其制备方法 | |
CN104706688A (zh) | 一种肉豆蔻总木脂素有效部位的制备方法 | |
CN102613655A (zh) | 一种银杏大蒜苦丁茶复合颗粒饮料 | |
CN102641352A (zh) | 一种柳茶有效部位提取物及其制备方法和用途 | |
CN104547026B (zh) | 一种丹参叶三七提取物的制备方法及其应用 | |
CN102626168A (zh) | 一种银杏叶提取工艺及银杏苦丁茶的加工方法 | |
CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
CN101167888A (zh) | 一种降压调脂的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221216 |